Search results
Alvotech. Our approach. We believe that a vertically integrated approach, from cell line development through fill and finish manufacturing, gives us the control, scale and speed needed to achieve our mission.
Alvotech. Better Access. Better Lives. We are led by science, driven by passion, and committed to biosimilars. We are continually evaluating additional pipeline opportunities to bring a strategic and robust selection of treatment options to patients around the world.
Join our team. Here at Alvotech, we want our employees to feel inspired in their careers and challenged by interesting and meaningful work. That’s why we are proud of our purpose-driven culture and the science we invest in.
Alvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities.
1 day ago · Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a ...
Find the latest Alvotech (ALVO) stock quote, history, news and other vital information to help you with your stock trading and investing.
Alvotech is a biopharmaceutical company focused on the creation of biosimilar medicines. It is engaged in the development and manufacture of biosimilar monoclonal antibodies for the treatment of cancer, autoimmune, inflammatory, and other diseases.
Alvotech | 27,566 followers on LinkedIn. Better Access. Better Lives. | Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the ...
Apr 24, 2024 · In November 2023 Alvotech announced positive topline results from a pharmacokinetic study (NCT05632211) for AVT05, which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to EU approved Simponi and US-licensed Simponi in 336 healthy adult subjects.
Jan 10, 2024 · Approval for the Uzpruvo biosimilar is based on comprehensive package comprising analytical, non-clinical and clinical similarity data, including the AVT04-GL-301 confirmatory comparative efficacy and safety clinical trial in patients with moderate to severe chronic plaque-type psoriasis.
